Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to hepatitis C treatment

International Journal of Medical Sciences

Volumn 7, Issue 1, 2010, Pages 36-42

  Suwantarat, Nuntra ^a   Tice, Alan D ^a,b   Khawcharoenporn, Thana ^a   Chow, Dominic C ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Infections Limited Hawaii   (United States)

Author keywords

Hepatitis C; Leukopenia; Pegylated interferon; Ribavirin; Thrombocytopenia; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD; WEIGHT REDUCTION;

EID: 76149126763     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.36     Document Type: Article

References (29)

1. Lauer GM, Walker BD. Hepatitis C virus infection: Medical progress. N Engl J Med 2001; 345: 41-51.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C infection in the United States, 1999 through 2002. Ann Intern Med 2006; 1444: 705-14.
4. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2002; 36: S21-9
5. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006; 57: 570-2.
6. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.
7. Krook AL, Stokka D, Hegar B, et al. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of Norwegian pilot study. Eur Addict Res 2007; 13: 216-21.
8. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b and ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 23-9.
9. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16-24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
10. Wenger C, Bischof T, Gonvers JJ, et al. Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. Swiss Med Wkly 2007; 137: 418-23.
11. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
12. Males S, Gad RR, Esmat G, et al. Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007; 1215: 797-803.
13. Yu JW, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha- 2a and ribavarin. J Gastroenterol Hepatol 2007; 22: 832-36.
14. Backus LI, Boothyroyd DB, Phillips BR, et al. Predictors of response of U.S. Veterans to treatment for Hepatitis C virus. Hepatology 2007; 46: 37-47.
15. Lo Re V 3rd, Kostman JR, Gross R, et al. Incidence and risk factors for weight loss during dual HIV/Hepatitis C virus therapy. J Acquir Immune Defic Syndr 2007; 44: 344-50.
16. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
18. Lindsay KL, Morishima C, Wright EC, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 234-41.
19. Ge D, Fellay J, Thompson AJ, et al. Genetic Variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461: 399-401.
20. Widjaja A, Wedemeyer H, Tillmann HL, et al. Hepatitis C and leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand Gastroenterol 2001; 36: 426-31.
21. Tilg H, Vogel W, Dinarello CA. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 1995; 85: 433-5.
22. Seyam MS, Freshwater DA, O'Donnell K, et al. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J viral Hepat 2005; 12: 531-5.
23. Matarese G, La Cava A. The intricate interface between immune system and metabolism. Treds Immunol 2004; 25: 193-200.
24. Enjoji M, Nakamuta M, Iwao M, et al. Leptin response in patients undergoing interferon therapy. J Clin Gastroenterol 2002; 34: 287-8.
25. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50.
26. Sulkoski M. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005; 9: 601-16.
27. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.
28. Perry CM, Wagstaff AJ. Interferon-alpha-n1: A review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis. BioDrug 1998; 9: 125-54.
29. Turbide C, Soulellis C, Deschenes M, et al. Does a decline in the hematological and biological parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? Can J Gastroenterol 2008; 22: 149-52.